Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
Higher output per batch allows the same quantity to be manufactured in fewer batches, freeing capacity for other portfolio products.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alvotech (ALVO) has received FDA approval for a new SIMLANDI manufacturing process that more than doubles drug substance output per batch.
The approval permits Process 2.0 in the company's DSM2 manufacturing suite in Reykjavik, Iceland. SIMLANDI (adalimumab-ryvk) is a biosimilar to Humira. The process increases output without changing the upstream manufacturing scale. Development, transfer and validation demonstrated comparability with the previously approved process, maintaining product quality, safety and efficacy.
Alvotech said producing the same quantity in fewer batches frees capacity for other portfolio products and provides greater flexibility to meet growing demand using existing infrastructure. The company also recently received FDA approval for additional manufacturing capacity.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointDrug substance output per batch more than doubles without changing the upstream manufacturing scale.
- Minor pointFDA approval permits Process 2.0 for SIMLANDI drug substance manufacturing in Reykjavik's DSM2 suite.
- Minor pointProcess validation demonstrated comparability with the previously approved process, maintaining product quality, safety and efficacy.
- Minor point. Forward-looking: it has not happened yet and may not happen.Fewer batches free capacity for other portfolio products, Alvotech said.
- Minor pointAdditional manufacturing capacity also recently received FDA approval.
Negative
- None.
Details
Market Reaction – ALVO
On Oct 20, the day this news came out, the latest delayed price for ALVO is 7.95% above the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $5.43.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Drug substance output per batch
- More than doubles
- New SIMLANDI manufacturing process; upstream manufacturing scale unchanged
Previous Fda approval Reports
-
FDA approval enabled drug-substance production in a second Reykjavik suite, doubling available U.S. supply capacity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biosimilar medical
drug substance technical
process validation technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio
REYKJAVIK, Iceland and LONDON, UK (October 20, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced
that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech’s biosimilar to Humira® (adalimumab).
The FDA approval allows Alvotech to introduce Process 2.0 for the manufacture of adalimumab drug substance in its DSM2 manufacturing suite in Reykjavik, Iceland. The new process more than doubles drug substance output per batch without changing the upstream manufacturing scale.
The improvement was achieved through targeted process development, effective process transfer and successful process validation, with demonstrated comparability to the previously approved process, maintaining product quality, safety and efficacy.
“More than doubling drug substance output per batch while maintaining product quality is a significant achievement that reflects the expertise of our process development and manufacturing teams,” said Joseph McClellan, Chief Operating Officer of Alvotech. “The new process allows us to manufacture the same quantity of drug substance in fewer batches, freeing up capacity to support other products in our portfolio, making better use of our existing infrastructure and giving us greater flexibility to respond to growing demand. Together with the recent FDA approval of additional manufacturing capacity, this demonstrates the strength of our operations in Reykjavik and reinforces our ability to deliver reliable supply to our commercial partners as demand for our biosimilars continues to grow.”
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Alvotech's FDA approval for the new SIMLANDI manufacturing process allow?
The approval allows Alvotech to introduce Process 2.0 for adalimumab drug substance manufacturing in its DSM2 suite in Reykjavik, Iceland. The process more than doubles output per batch without changing the upstream manufacturing scale.